DARZALEX
PeakmAbBLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
7/8 — Comprehensive
Priority Review
DARZALEX by Johnson & Johnson is cd38 is a transmembrane glycoprotein (48 kda) expressed on the surface of hematopoietic cells, including clonal plasma cells in multiple myeloma and light chain (al) amyloidosis, as well as other cell types. Approved for lenalidomide, dexamethasone for induction, consolidation in newly diagnosed patients and 11 more indications. First approved in 2015.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARZALEX (daratumumab) is a CD38-directed monoclonal antibody approved in November 2015 for treating multiple myeloma. It works by binding to CD38 on plasma cells, triggering immune-mediated cell death through multiple mechanisms including ADCP, ADCC, and CDC. The drug is currently at peak lifecycle stage with established market presence.
$0.016BPart D
PeakEstablished peak-stage asset generating substantial Part D volume with significant commercial infrastructure, suggesting stable team sizing and mature go-to-market execution.
Mechanism of Action
CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including clonal plasma cells in multiple myeloma and light chain (AL) amyloidosis, as well as other cell types. Surface CD38 has multiple functions, including receptor mediated adhesion, signaling, and…
Indications (14)
Worked on DARZALEX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.